Drug Approval | April 06, 2024
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The average time of dilation lasts three to eight hours
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
To accelerate the development of next-generation radioconjugates to treat cancer
Subscribe To Our Newsletter & Stay Updated
